Kristi Rosa
Associate Editorial Director at OncLive
associate editorial director of @OncLive. bibliophile. foodie. cat mom. opinions are my own.
Articles
-
2 days ago |
onclive.com | Kristi Rosa
The PRAME-directed TCR T-cell therapy IMA203 displayed acceptable tolerability and showcased early clinical activity in patients with PD-1–refractory metastatic melanoma, according to data from a phase 1 study (NCT03686124) presented during the 2025 ASCO Annual Meeting.1With regard to safety, the trial’s primary end point, the most common treatment-emergent adverse effects (TEAEs) were anticipated cytopenias linked with lymphodepleting chemotherapy.
-
3 days ago |
targetedonc.com | Kristi Rosa
Neoadjuvant nivolumab (Opdivo) in combination with chemotherapy elicited a statistically significant and clinically meaningful overall survival (OS) improvement vs chemotherapy alone in patients with resectable non–small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate-816 study (NCT02998528) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 At a median follow-up of 68.4 months, the median OS was not reached (NR) with nivolumab...
-
4 days ago |
onclive.com | Kristi Rosa
The addition of relatlimab to nivolumab (Opdivo) failed to significantly improve recurrence-free survival (RFS) vs nivolumab alone in patients with completely resected stage III to IV melanoma, according to the primary and final results of the phase 3 RELATIVITY-098 study (NCT05002569) presented during the 2025 ASCO Annual Meeting.1 The median RFS with nivolumab/relatlimab (n = 547) was not reached (NR; 95% CI, 30.8-NR) by investigator assessment vs 33.1 months (95% CI, 31.0-NR) with...
-
4 days ago |
cancernetwork.com | Kristi Rosa
A statistically significant and clinically meaningful overall survival (OS) benefit was observed when neoadjuvant novolumab (Opdivo) plus chemotherapy vs chemotherapy alone was used to treat patients with resectable non–small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate-816 study (NCT02998528) presented during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
-
4 days ago |
onclive.com | Kristi Rosa
Neoadjuvant nivolumab (Opdivo) plus chemotherapy provided a statistically significant and clinically meaningful overall survival (OS) benefit vs chemotherapy alone in patients with resectable non–small cell lung cancer (NSCLC), according to findings from the phase 3 CheckMate-816 study (NCT02998528) presented during the 2025 ASCO Annual Meeting.1 At a median follow-up of 68.4 months, the median OS was not reached (NR) with nivolumab plus chemotherapy (n = 179) vs 73.7 months with chemotherapy...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 435
- Tweets
- 1K
- DMs Open
- No
RT @OncLive: Happy International Women’s Day! 💜 A heartfelt thank you to the incredible panel of women who led the 2nd Annual Women in Onco…
RT @OncLive: 🚨 Takeover Alert! 🚨 This #InternationalWomensDay, we're handing over the mic to 2 powerhouse female oncologists: @heMEGirl_MD…
RT @OncLive: It's time for this week's #OncFive 5️⃣, our top 5 articles in #oncology. Check it out: https://t.co/q8uKNj3ABG https://t.co/AM…
